7q11.23 deletions in Williams syndrome arise as a consequence of unequal meiotic crossover by Urban Z, et al.
Letters to the Editor
Am. J. Hum. Genet. 59:958-962, 1996
7q1 1.23 Deletions in Williams Syndrome Arise as a
Consequence of Unequal Meiotic Crossover
To the Editor:
Williams syndrome (WS) (Williams et al. 1961; Beuren
et al. 1962) is a multisystem disorder characterized by
mental retardation, a specific neurobehavioral profile,
characteristic facies, infantile hypercalcemia, cardiovas-
cular abnormalities, progressive joint limitation, her-
nias, and soft skin. Recent studies have shown that hemi-
zygosity at the elastin (ELN) gene locus on chromosome
7q is associated with WS (Ewart et al. 1993). Further-
more, two FISH studies using cosmid recombinants con-
taining the 5' or the 3' end of the ELN gene revealed
deletion of the entire ELN gene in 90%-96% of classi-
cal WS cases (Lowery et al. 1995; Nickerson et al. 1995).
However, the size of the 7ql 1.23 deletions and the
mechanism by which these deletions arise are not
known.
To begin to understand the complex genetic defect
underlying the pathogenesis of WS, we describe in this
letter a high-resolution genetic map of the qi 1 region of
chromosome 7 and use several of these linked markers,
including a new and highly informative tetranucleotide-
repeat polymorphism within the first intron of the ELN
gene, for haplotype analysis of 31 WS patients and unaf-
fected family members. This study provides for the first
time both an estimate of the size of the 7ql 1.2 deletions
in WS and an insight into the mechanism responsible
for the generation of these 7q deletions.
We analyzed 7q deletions in a total of 31 sporadic
WS patients, by haplotype analysis. Diagnostic criteria
included characteristic facies, mental retardation, and
gregarious personality. More than 65% of these patients
had supravalvular aortic stenosis (SVAS), as evidenced
by echocardiography. Peripheral whole-blood samples
were collected with informed consent of the patients and
family members, and total genomic DNA was isolated.
Patients and family members were genotyped for three
ELN gene markers. These included a new tetranucleo-
tide-repeat polymorphism within the first intron
(ELNil), a CA-repeat polymorphism within intron 18
(ELNi18; Foster et al. 1993), and an RmaI RFLP within
exon 20 of the ELN gene (ELNe20; Tromp et al. 1991).
The new ELN gene marker within intron 1 was detected
by primers HEI1.3S (5'-GCCCACATGGGCAGA-
TTGCT-3') and HEI1 .4A (5'-CCCTCATCCACAGAC-
AGGTC-3'). PCR-amplification conditions used with
these oligomers were as follows: a S-25-,ul reaction con-
tained a final concentration of 1.5 mM MgCl2, 0.2 mM
of each dNTP, 1 gM HEI1.3S, 0.8 ,uM HEI1.4A, 0.2
gM P32-HEI1.4A (5' end-labeled), 25 units x AmpliTaq
polymerase/ml (Perkin-Elmer), and 5 jg total genomic
DNA/ml. Amplification reactions were performed with
a thermal cycler (GeneAmp System 9600, Perkin-Elmer),
which was programmed for 25 cycles, each cycle of
which consisted of a 94°C incubation for 30 s, a 60°C
incubation for 30 s, and a 72°C incubation for 30 s.
Products were separated on denaturing acrylamide gels
and were visualized by autoradiography. In addition to
the ELN gene markers, the following polymorphisms
were used for haplotype analysis: D7S672 (probe AF-
M289ve9), D7S653 (probe AFM2S9zc1), D7S1870
(probe AFMaO6Oxc9), D7S849 (probe 1129AC/TG),
D7S675 (probe AFM295yg9), and D7S634 (probe
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Figure 1 Microsatellite map of the midsection of chromosome 7 containing the ELN gene. Markers were placed with 1,000:1 odds for
order. Nonuniquely placed markers are shown to the left of the sex-average map, associated with unbroken vertical bars to indicate their map
intervals. The three maps were prepared with different scale factors and cover 56 cM in the female map, 27 cM in the male, and 43 cM when
sex is not considered (the sex-average map). Map distances are in Kosambi centimorgans. Tie-lines to the chromosome 7 ideogram indicate
cytogenetic placement of markers on the chromosome. Detailed description of the mapping procedures and further data on the new polymorphism
ELNil are available through the World Wide Web Genlink resource (http://www.genlink.wustl.edu).
AFM203vb6). These markers were detected as described
in the Genome Database (Weissenbach et al. 1992; Gya-
pay et al. 1994; Iles et al. 1994).
To investigate the size of deletions associated with
WS, we generated a high-resolution linkage map of the
chromosomal region containing the ELN gene (fig. 1).
We could uniquely place polymorphic locus D7S1870
on the 1994 Chromosome 7 Workshop report's micro-
satellite-marker map (Helms et al. 1995) by adding ge-
notype data for the ELN and D7S1870 loci. D7S1870
was located telomeric to the ELN gene, at a distance of
0.9 cM.
The 31 WS patients and unaffected family members
were genotyped with the three ELN gene markers and
the polymorphic loci located proximal (D7S672 and
D7S653) and distal (D7S1870, D7S849, D7S675, and
D7S634) to the ELN gene locus, as determined by our
high-resolution genetic map (fig. 1). D7S849 could not
be placed on the map, because of the moderate informa-
tivity of the marker (heterozygosity .56). However, the
position of D7S849 relative to other markers used in
this study could be established on the basis of the fact
that it segregated with marker alleles distal to the ELN
gene (fig. 2).
Genotype data were subsequently used to generate
haplotypes to study the inheritance of deleted and unde-
leted markers. The ELN gene markers detected hemizy-
gosity in 25 informative WS patients (table 1). Similarly,
one allele represented by D7S1870 was found to be de-
leted in 27 informative WS patients (table 1). A simulta-
neous deletion of the ELN gene locus and D7S1870 was
observed in 23 patients informative for markers in both
loci. Our genetic map locates D7S1870 0.9 cM distal
to ELN.
Another distal locus, D7S849, was found to be hemi-
zygous in 4 (13%) of the 31 patients, suggesting size
heterogeneity of the WS deletion. Proximal loci D7S672
and D7S653 and distal loci D7S675 and D7S634, on
the other hand, were found to be heterozygous in all
informative WS patients, indicating that the location of
these markers falls outside the region deleted in WS
(table 1). On the basis of genetic mapping of these unde-
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Figure 2 Haplotype analysis ofWS families. Patients and family
members were genotyped for markers indicated in the boxed list, in
proximal to distal order. The order of the ELN markers is arbitrary,
since the orientation of the ELN gene on the chromosome is unknown.
The three representative families (families 1-3) of patients 1124,
1093, and 1420, respectively, are shown. One maternal chromosome
is identified by an empty box, and one paternal chromosome is indi-
cated by shading. del = allele deleted; * = allele identity inferred; and
n/del = uninformative (n = any allele number).
leted markers, the proximal locus D7S653 (1.6 cM) and
the distal locus D7S675 (0-7.5 cM) were located nearest
to the chromosomal region deleted in WS patients.
Taken together, mapping and genotype data indicate
that the deletion in WS patients involves a genetic dis-
tance of 0.9-2.5 cM on the sex-average map (the dis-
tance between markers D7S653 and D7S1870).
Deletions were located on the paternal chromosome
in 12 patients (41%) and on the maternal chromosome
in 17 patients (59%). x2 Analysis revealed no statisti-
cally significant difference (P < .1) between the maternal
and paternal distribution of the WS deletions. Clearly,
deletions in WS patients can occur on chromosome 7
derived from either parent.
We identified 12 families that were simultaneously
informative for proximal, deleted, and distal markers
and that had at least one unaffected sibling of the WS
patient, to allow for the determination of chromosomal
phase. We observed that WS patients in all of these 12
families not only were deleted for at least one marker
in the ELN gene region but also had an apparent recom-
bination between proximal and distal markers flanking
the deletion (fig. 2). In contrast, homologue chromo-
somes in the same WS patients did not show any recom-
bination event between these proximal and distal mark-
ers. These data strongly implicate meiotic recombination
as an underlying mechanism of the generation of dele-
tions causing WS.
In conclusion, our genotype data demonstrate the
simultaneous deletion of ELN and D7S1870 in 23 WS
patients. Furthermore, we have shown by genetic
mapping that D7S1870 is located distal to the ELN
gene and that the genetic distance between ELN and
D7S1870 is 0.9 cM. These mapping and haplotype
studies together indicate that a large portion of geno-
mic DNA distal to the ELN gene that spans 0.9-2.5
cM is missing in most WS patients with SVAS. Al-
though physical distances corresponding to a given
genetic distance vary depending on the genomic region
studied (Chumakov et al. 1995), our results are consis-
tent with deletions spanning a region of 1-2.5 Mb
including the ELN gene in WS patients. Clearly, there-
fore, deletions at 7q11.2 in WS patients are suffi-
ciently large to affect several genes, including the ELN
gene. WS therefore may indeed be a contiguous gene-
deletion syndrome. In confirmation of these results,
the gene for replication factor C subunit 2, RFC2, has
most recently been shown to be deleted in WS patients
(Peoples et al. 1996).
Our haplotype data demonstrate a high frequency of
recombination between markers flanking the deletion in
WS patients, suggesting that the large, 0.9-2.5-cM de
novo deletions that we have reported are the result of
unequal crossing-over during meiosis. The high fre-
quency of such de novo deletions suggests that genomic
regions flanking the ELN locus are particularly suscepti-
ble to meiotic mispairing.
Unequal crossover events produce both deletions
and duplications. Therefore, in addition to the 0.9-
cM deletions that we have observed in WS patients, it
is probable that a duplication abnormality also exists,
involving a genomic region of 0.9-2.5 cM including
the ELN gene. Individuals carrying such hypothetical
duplications on 7q are likely to be born at the same
frequency as are WS patients. Such paired microdele-
tion and duplication abnormalities are not unprece-
dented among human genetic diseases. For example,
two dominantly inherited neurodegenerative diseases
(hereditary neuropathy with liability to pressure pal-
sies and Charcot-Marie-Tooth disease type 1A) are
caused by the deletion and duplication, respectively,
of the same 1.5-Mb region on chromosome 17p (for
review, see Suter and Patel 1994; Lupski et al. 1996).
Similarly, WS and a hypothetical duplication abnor-
mality with a similar or unrelated phenotype may be
another example of such paired deletion-duplication
mutational events.
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Table 1
Genotypes of 31 WS Patients, for Polymorphic Markers within and Flanking the Elastin Gene, as Determined by Haplotype Analysis of the
Respective Families
Patient D7S672 D7S653 ELNil ELNi18 D7S1870 D7S849 D7S675 D7S634 Recombination'
1124 1-3 6-7 4-del 2-del 7-del 2-? 2-4 7-4 Present
1151 3-3 5-7 6-del 4-? 13-del 3-del 2-4 5-6 ?
1081 1-12 6-1 del-3 ?-2 del-12 2-5 3-3 6-3 ?
1093 ?-3 ?-7 del-5 ?-2 ?-11 1-2 4-2 3-5 Present
1089 5-1 8-2 ?-4 ?-2 del-11 ?-2 2-4 4-2 ?
1138 9-3 4-7 ?-5 ?-2 ?-10 ?-5 3-5 5-5 ?
1420 7-1 1-6 4-del 2-? 7-del 2-? 4-2 2-4 Present
1172 n.d. 5-6 del-5 ?-2 del-10 2-5 4-6 4-5 ?
1A 6-3 7-1 del-2 ?-5 ?-10 5-2 5-5 5-5 ?
2A 3-8 7-1 7-del 2-? 10-del 5-3 3-4 5-5 ?
3A 7-13 1-? 6-del 4-del 10-del 2-4 4-2 4-5 ?
SA 11-12 5-1 del-6 ?-2 del-12 2-1 5-4 3-4 ?
6A ?-3 ?-7 del-4 del-2 del-7 2-8 3-4 4-5 Present
7A 8-8 1-4 del-5 ?-2 del-8 ?-2 ?-2 6-3 Present
8A 7-2 ?-1 ?-5 del-4 del-13 ?-2 5-2 5-4 ?
9A ?-3 ?-7 ?-4 del-2 del-12 2-5 n.d. 4-6 ?
10A 3-? 7-? 5-del 2-? 10-del 5-? 3-4 4-4 ?
11A 3-? 7-? 4-? 2-? 7-del 2-? 5-4 3-6 ?
12A 5-3 ?-7 del-4 ?-2 del-6 del-6 2-4 3-3 ?
13A ?-3 ?-7 del-4 ?-2 del-9 6-2 2-2 3-4 Present
14A 4-3 7-6 6-del 2-? 9-del 4-del 1-4 4-3 Present
16A 3-3 8-5 del-8 del-7 del-10 ?-2 ?-4 3-5 Present
19A 2-2 1-7 ?-4 ?-2 del-11 4-5 2-2 5-5 ?
20A 8-12 1-? 4-del 5-del 10-del 2-del 4-3 4-5 Present
21A 3-? 7-? 5-? 2-? 8-del 2-? 2-? 1-3 ?
22A 3-3 7-5 del-3 del-5 del-10 6-2 5-4 3-4 Present
25A 11-1 1-? 5-del 6-del 7-del 5-? 3-4 3-2 Present
26A 8-6 1-? 4-del 2-del 10-del 2-5 3-4 4-4 Present
28A 8-5 ?-1 ?-5 del-2 del-7 2-5 4-4 5-3 ?
29A 3-11 7-1 ?-6 ?-4 ?-10 7-2 4-3 5-6 Present
33A 3-4 ?-7 del-7 del-4 del-10 ?-5 4-5 1-6 ?
NOTE.-Marker loci are listed in proximal to distal order, from left to right. Genotype data are represented with the identification number
of the maternal allele on the left and with the paternal allele on the right. del = marker allele deleted; ? = uninformative; and n.d. = no data.
a Between the proximal and distal markers on the deletion chromosome.
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A Somatic Truncating Mutation in BRCA2 in a
Sporadic Breast Tumor
To the Editor:
Recently, a second susceptibility gene for hereditary
breast and ovarian cancer, BRCA2, was cloned (Woos-
ter et al. 1995; Tavtigian et al. 1996). The subsequent
identification of heterozygous germ-line mutations con-
firmed its role as a predisposing factor in a subset of
familial breast and ovarian cancer families (Wooster et
al. 1995; Lancaster et al. 1996; Miki et al. 1996; Tavtig-
ian et al. 1996; Teng et al. 1996). The possible involve-
ment of BRCA2 in the sporadic forms of breast and
ovarian tumors was addressed in three recent reports
analyzing the gene for somatic mutations in 212 primary
breast cancers and 55 ovarian cancers (Lancaster et al.
1996; Miki et al. 1996; Teng et al. 1996). Although
several alterations were identified, all except two
changes were shown to represent germ-line mutations.
Moreover, the two somatic BRCA2 alterations were
found to be missense mutations resulting in a Asp3095-
Glu change (Lancaster et al. 1996) in one case and in a
His2415Asn change (Miki et al. 1996) in the other.
Given the questionable effect of missense mutations on
protein function, the role of BRCA2 in the carcinogene-
sis of sporadic breast tumors remains unclear.
In order to identify in primary breast cancers the so-
matic BRCA2 mutations with clear functional conse-
quences, we have analyzed the three large exons- 10,
11, and 27-of BRCA2, together constituting 65% of
the coding region of the gene (Tavtigian et al. 1996), in
69 unselected samples of frozen breast tumor sections,
using the protein-truncation test (PTT) (Roest et al.
1993). Here we report a first case of a truncating somatic
mutation in BRCA2 in a primary ductal breast carci-
noma with demonstrated loss of heterozygosity (LOH).
PTT was utilized to identify protein-termination muta-
tions in exons 10, 11, and 27 of BRCA2, using genomic
DNA and oligonucleotide primers PTT10 f/r (5'-CTT-
AATACGACTCACTATAGGGAGACCACCATGTAT-
ACTTTAACAGGA'Fl'IGGAA-3' /5'-ACACAGAAGG-
AATCGTCATC-3'), the overlapping primer sets PTT1l1A
f/r (5'-CTfJTAATACGACTCACTATAGGGAGACCACC-
ATG'l-ITI'lATGTTTAGGTFITATTGC-3'/5'-TGCATTf-
CCTCAGAAGTGGTC-3'), PTT11lB f/r (5'-CTTAAT-
ACGACTCACTATAGGGAGACCACCATGAAACCA-
AGCTACATATTGCAG-3'/5'-TAA7'l I CCTACATAA-
TCTGCAG-3'), PTT11C f/r (5'-CTTA ATACGACT-
CACTATAGGGAGACCACCATGTGGCTTAGAGAA-
GGAATATTTG-3'/5'-AAAATAGTGATTGGCAAC-
ACG3'), and the primer set P1T27 f/r (5'-CTTAATACG-
ACTCACTATAGGGAGACCACCATGACGT7'l' I'CA-
TTTTTTTATCA-3'/5' -ATAATTTATTGTCGCC-
'lIT'GC-3'). SDS-PAGE analysis of translated PCR prod-
uct PTT1 lA r/f revealed a truncated protein of -35 kD
in breast tumor tissue but not in blood lymphocytes of
patient Sp27 (fig. la). The genetic identity of tumor and
lymphocyte DNA in patient Sp27 was verified by informa-
tive markers at DllS524 and DllS554 (data not shown)
and was also confirmed at D13S260 and D13S171 (fig.
lb). Sequencing of the variant P11 allele in the approxi-
